Why Choose Dexcom for Patient Care

See why Dexcom is the right choice for optimizing glucose control.

Dexcom is Revolutionizing Diabetes Care.

Dexcom is dedicated to developing innovative glucose sensing technology and products to help patients and healthcare providers better manage diabetes.

As the provider of the number one patient-preferred CGM system,1 Dexcom invites you to take a look at the Dexcom G6, a revolution in diabetes management.

  • Mobile CGM system
  • CGM system indicated for non-adjunctive use (insulin dosing without fingersticks*) 
  • Therapeutic CGM system covered by Medicare
  • Integrated CGM–an FDA-designation meeting rigorous performance standards

*If your glucose alerts and readings from the Dexcom G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

Dexcom is Redefining CGM.

From "snapshot" glucose readings to continuous glucose monitoring (CGM) systems that provide real-time, around-the-clock data, Dexcom is defining a new chapter in diabetes therapy management with a revolutionary, no-fingerstick iCGM system.*

CGM Evolution Infographic

Dexcom is a Leader in Accuracy & Reliability.

Dexcom G6 Performance Metrics2

With an overall MARD of 9% and a sustained accuracy over time,2 the Dexcom G6 demonstrates exceptional accuracy.

  %15/15* %20/20 MARD
Overall§ 83.3% 93.9% 9.0%
ACCURACY OVER TIME
Day 1
Day 2
Day 4-5
Day 7
Day 10
81.5%
84.0%
85.8%
82.1%
82.4%
92.2%
92.3%
95.5%
97.3%
92.5%
9.3%
8.4%
9.4%
8.7%
9.0%

Accuracy at Various Rates of Change3

Rising or falling, Dexcom G6 demonstrates accuracy through slow and rapid rates of change.3

CGM RATE OF CHANGE
(mg/dL per min)
%20/20

< -2
[-2,-1)
[-1,0)
[0,1)
(1,2]
> 2

 

89.7%
93%
93.9%
92.7%
89.6%
87.1%

 

Dexcom G6 Performance Summary

Dexcom is Defining a New Standard in Diabetes Management.

Smart device compatibility

Smart device sold separately.

Zero fingersticks* with Dexcom G6

*If your glucose alerts and readings from the Dexcom G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

Accuracy during critical times4

Improved glycemic outcomes (multiple measures)5-9

Real-time glucose data sharing

Customizable high and low alerts

Get the Most Out of Patient Visits at the Clinic

With easy data sharing, providers can access CGM reports that show patterns, trends or specific data for each patient. Learn more about Dexcom CLARITY and how you can incorporate patient CGM data at the clinic.

Data Analysis - Downloadable Reports

Widespread Coverage

Dexcom CGM is covered as a medical benefit for 98% of commercial insurance plan holders who have type 1 diabetes, and a growing number of plans cover CGM for insulin-using type 2 diabetes patients. For people whose plans cover CGM as a pharmacy benefit, their Dexcom CGM prescription may be processed at local retail pharmacies. Dexcom CGM is covered by Medicare - the first mobile-enabled, therapeutic CGM to achieve Medicare coverage, and by Medicaid.

Why-Dexcom_Widespread-Coverage

Feature Comparison with Dexcom G6

Dexcom G6 is the first and only CGM system classified as an integrated CGM device. Click on each tab below to compare CGM product features.

Features Dexcom G6 FreeStyle Libre 14 day
Routine fingersticks needed No No
Continuous data availability Yes No (user must scan sensor)
Factory-calibrated  Yes (can be manually calibrated) Yes
Indicated for use in diabetes treatment decisions Yes Yes
Age indication (years) 2+ 18+
Self-insertion and removal of sensor Yes Yes
Proactive/predictive alerts Yes No
Warmup period 2 hours 1 hour (confirmatory fingerstick required during first 12 hours of sensor use) 
Sensor life 10 days 14 days
Meets requirements for integrated CGM device Yes No
Data sharing Yes

No

Mobile device connectivity Yes (iOS and Android) Yes (iOS only)
Medicare coverage Yes Yes
Performance Dexcom G6 FreeStyle Libre 14 day
Published MARD 9.0%* (overall) 10.1%*

Performance data is not from head-to-head studies.

*The information and data contained in this table were obtained from each manufacturer’s product user guide: Dexcom (Dexcom G6 CGM System User Guide, 2018); Abbott FreeStyle Libre 14 Day Flash Glucose Monitoring System, Summary of Safety and Effectiveness Data (SSED), July 2018; Medtronic (Guardian Connect System User Guide, 2018); Senseonics (Eversense CGM User Guide, 2018). If glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, during the first 12 hours of sensor use, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose. ||G6 readings can be used to make diabetes treatment decisions when taking up to a maximum acetaminophen dose of 1,000 mg every 6 hours. Taking a higher dose may affect the G6 readings. MARD data shown based on calibrations every 12 hours; published MARD with calibration 3-4 times/day: 9.6% (abdomen); 8.9% (arm). 

Features Dexcom G6 Guardian Connect
Routine fingersticks needed No Yes
Continuous data availability Yes Yes
Factory-calibrated Yes (can be manually calibrated) No (minimum of 2 fingerstick calibrations/day; 3-4 recommended)
Indicated for use in diabetes treatment decisions Yes No
Age indication (years) 2+ 14-75
Self-insertion and removal of sensor Yes Yes
Proactive/predictive alerts Yes Yes
Warmup period 2 hours 2 hours
Sensor life 10 days 7 days
Meets requirements for integrated CGM device Yes No
Data sharing Yes Yes
Mobile device connectivity Yes (iOS and Android) Yes (iOS only)
Medicare coverage Yes No
Performance Dexcom G6 Guardian Connect
Published MARD 9.0%* (overall) 10.6%* (abdomen)9.1%* (arm)

Performance data is not from head-to-head studies.

*The information and data contained in this table were obtained from each manufacturer’s product user guide: Dexcom (Dexcom G6 CGM System User Guide, 2018); Abbott FreeStyle Libre 14 Day Flash Glucose Monitoring System, Summary of Safety and Effectiveness Data (SSED), July 2018; Medtronic (Guardian Connect System User Guide, 2018); Senseonics (Eversense CGM User Guide, 2018). If glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, during the first 12 hours of sensor use, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose. ||G6 readings can be used to make diabetes treatment decisions when taking up to a maximum acetaminophen dose of 1,000 mg every 6 hours. Taking a higher dose may affect the G6 readings. MARD data shown based on calibrations every 12 hours; published MARD with calibration 3-4 times/day: 9.6% (abdomen); 8.9% (arm). 

Features Dexcom G6 Eversense CGM System
Routine fingersticks needed No Yes
Continuous data availability Yes Yes
Factory-calibrated Yes (can be manually calibrated) No (2 calibrations/day required)
Indicated for use in diabetes treatment decisions Yes No
Age indication (years) 2+ 18+
Self-insertion and removal of sensor Yes No (requires surgical incision and removal by a trained physician)
Proactive/predictive alerts Yes Yes
Warmup period 2 hours 24 hours; daily 15-minute transmitter recharge
Sensor life 10 days 90 days
Meets requirements for integrated CGM device Yes No
Data sharing Yes Yes
Mobile device connectivity Yes (iOS and Android) Yes
Medicare coverage Yes No
Performance Dexcom G6 Eversense CGM System
Published MARD 9.0%* (overall)  8.5%*, 9.6%*

Performance data is not from head-to-head studies.

*The information and data contained in this table were obtained from each manufacturer’s product user guide: Dexcom (Dexcom G6 CGM System User Guide, 2018); Abbott FreeStyle Libre 14 Day Flash Glucose Monitoring System, Summary of Safety and Effectiveness Data (SSED), July 2018; Medtronic (Guardian Connect System User Guide, 2018); Senseonics (Eversense CGM User Guide, 2018). If glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol, during the first 12 hours of sensor use, when symptoms do not match system readings, when you suspect readings may be inaccurate, or when you experience symptoms that may be due to high or low blood glucose. ||G6 readings can be used to make diabetes treatment decisions when taking up to a maximum acetaminophen dose of 1,000 mg every 6 hours. Taking a higher dose may affect the G6 readings.MARD data shown based on calibrations every 12 hours; published MARD with calibration 3-4 times/day: 9.6% (abdomen); 8.9% (arm). 

Zero Fingersticks* with Dexcom G6

The factory-calibrated Dexcom G6 gives your patients the freedom to manage diabetes without the hassle of fingersticks for calibrations or treatment decisions.*

*If your glucose alerts and readings from the Dexcom G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

When sensor code is entered.

Why CGM

Dexcom CGM

What is CGM?

Learn how continuous glucose monitoring (CGM) is a powerful tool to help improve diabetes management.

Proven Outcomes of Dexcom CGM

Proven Outcomes

Review evidence demonstrating the impact CGM use can have on glycemic control.

Dexcom CGM Patient Benefits

Patient Benefits

Whether type 1 or type 2, injections or pump, your patients may benefit.

*% of CGM readings within ±15 mg/dL of YSI lab reference values ≤ 100mg/dL or ±15% of YSI values > 100mg/dL.
Analogous to %15/15 (see previous footnote).
MARD is a statistical measure of accuracy; the lower the number, the better.
§Unless noted otherwise, adult and pediatric data are combined.
IITreatment decisions should not be made based on Dexcom Follow.
Dexcom internal data on file

1 dQ&A Diabetes Connections Panel Report, Q4 2018
2 Shah VN, Laffel LM, Wadwa RP, Garg SK. Performance of a Factory-Calibrated Real-Time Continuous Glucose Monitoring System Utilizing an Automated Sensor Applicator. Diabetes Technol Ther. 2018.
3 Wadwa RP, Laffel LM, Shah VN, Garg SK. Accuracy of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System During 10 Days of Use in Youth and Adults with Diabetes. Diabetes Technol Ther. 2018.
4 Dexcom G6 CGM System User Guide, 2018
5 Šoupal J, Petruželková L, Fleka M et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technology & Therapeutics. 2016;18(9):532-538.
6 Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomised Clinical Trial. JAMA. 2017;317(4):371-378.
7 Lind M, Polonsky W, Hirsch IB, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomised Clinical Trial. JAMA. 2017;317(4):379-387.
8 Reddy M, Jugnee N, El Laboudi A, Spanudakis E, Anantharaja S, Oliver N. A randomised controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia. Diabet Med. 2017.
9 Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018.

Contact Dexcom

If you are a clinician and want to learn more about Dexcom’s Continuous Glucose Monitoring Systems, please fill out the form and a Dexcom representative will contact you.

If you are a Dexcom User or Patient, please contact Dexcom here.

The information you provide will be sent securely and subject to the Dexcom Terms of Use and Privacy Policy.